company background image
MYGN

Myriad Genetics NasdaqGS:MYGN Stock Report

Last Price

US$22.01

Market Cap

US$1.8b

7D

11.8%

1Y

-18.6%

Updated

16 May, 2022

Data

Company Financials +
MYGN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

MYGN Stock Overview

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally.

Myriad Genetics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Myriad Genetics
Historical stock prices
Current Share PriceUS$22.01
52 Week HighUS$36.95
52 Week LowUS$18.98
Beta1.57
1 Month Change-8.22%
3 Month Change-18.93%
1 Year Change-18.57%
3 Year Change-12.66%
5 Year Change4.07%
Change since IPO309.49%

Recent News & Updates

Shareholder Returns

MYGNUS BiotechsUS Market
7D11.8%4.8%0.7%
1Y-18.6%-22.0%-10.8%

Return vs Industry: MYGN exceeded the US Biotechs industry which returned -21.7% over the past year.

Return vs Market: MYGN underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is MYGN's price volatile compared to industry and market?
MYGN volatility
MYGN Average Weekly Movement8.0%
Biotechs Industry Average Movement12.3%
Market Average Movement7.8%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market2.9%

Stable Share Price: MYGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MYGN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19912,400Paul Diazhttps://myriad.com

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Myriad Genetics Fundamentals Summary

How do Myriad Genetics's earnings and revenue compare to its market cap?
MYGN fundamental statistics
Market CapUS$1.80b
Earnings (TTM)-US$8.20m
Revenue (TTM)US$682.40m

2.6x

P/S Ratio

-215.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MYGN income statement (TTM)
RevenueUS$682.40m
Cost of RevenueUS$195.30m
Gross ProfitUS$487.10m
Other ExpensesUS$495.30m
Earnings-US$8.20m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin71.38%
Net Profit Margin-1.20%
Debt/Equity Ratio0%

How did MYGN perform over the long term?

See historical performance and comparison

Valuation

Is Myriad Genetics undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MYGN ($22.01) is trading below our estimate of fair value ($50.89)

Significantly Below Fair Value: MYGN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MYGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MYGN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MYGN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MYGN is overvalued based on its PB Ratio (1.9x) compared to the US Biotechs industry average (1.4x).


Future Growth

How is Myriad Genetics forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


56.8%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MYGN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MYGN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MYGN's is expected to become profitable in the next 3 years.

Revenue vs Market: MYGN's revenue (8.9% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: MYGN's revenue (8.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (2.9%).


Past Performance

How has Myriad Genetics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-55.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MYGN is currently unprofitable.

Growing Profit Margin: MYGN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of 55.6% per year.

Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: MYGN has a negative Return on Equity (-0.86%), as it is currently unprofitable.


Financial Health

How is Myriad Genetics's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: MYGN's short term assets ($427.4M) exceed its short term liabilities ($166.0M).

Long Term Liabilities: MYGN's short term assets ($427.4M) exceed its long term liabilities ($139.3M).


Debt to Equity History and Analysis

Debt Level: MYGN is debt free.

Reducing Debt: MYGN has no debt compared to 5 years ago when its debt to equity ratio was 22.2%.

Debt Coverage: MYGN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: MYGN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Myriad Genetics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MYGN has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Paul Diaz (59 yo)

1.75yrs

Tenure

US$12,787,669

Compensation

Mr. Paul J. Diaz has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He served as a Partner at Cressey & Company LP since September 2017. Since Augu...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD12.79M) is above average for companies of similar size in the US market ($USD5.45M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: MYGN's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: MYGN's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.3%.


Top Shareholders

Company Information

Myriad Genetics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Myriad Genetics, Inc.
  • Ticker: MYGN
  • Exchange: NasdaqGS
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.797b
  • Shares outstanding: 80.34m
  • Website: https://myriad.com

Number of Employees


Location

  • Myriad Genetics, Inc.
  • 320 Wakara Way
  • Salt Lake City
  • Utah
  • 84108
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/16 00:00
End of Day Share Price2022/05/16 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.